Optimizing the Management of Heart Failure from Hospital to Home: Translating the Latest Evidence into Practice
September 12, 2019
September 12, 2020
Scroll to the Bottom of this Information to Begin this Course
This CME activity is provided by Integrity Continuing Education.
This CE activity is jointly provided by Global Education Group and Integrity Continuing Education.
Supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Pharmacists — maximum of 1.0 contact hour (0.10 CEUs).
- Nurses — 1.0 contact hour.
All other healthcare professionals completing this course will be issued a statement of participation.
This educational initiative is intended for internal medicine clinicians, hospitalists and all healthcare professionals involved with the diagnosis and management of patients with HF.
Although modern medicine has substantially improved outcomes in patients with heart failure (HF), the associated morbidity and mortality remain unacceptably high. Patients hospitalized with HF-related issues show poor outcomes following discharge, with 1 out of 10 not surviving 3 months and nearly 1 out of 3 rehospitalized within 1 year. Recently published guidelines from national and international organizations provide clear guidance to improve these outcomes, yet many recommendations are not followed. Guideline-directed medication therapy (GDMT) is essential to ensure patients receive appropriate care. Clinicians must thoroughly understand how to diagnose and assess these patients, as stages and functional classifications are necessary for determining management strategy. Up-to-date knowledge of medications, their places in GDMT is essential, as well as staying abreast of recent clinical trial data that outlines the appropriate in-hospital initiation of newer therapies in stabilized patients. Lastly, ensuring effective transitions of care is paramount to ensuring optimal outcomes, and clinicians must be aware of barriers to care and strategies for overcoming these obstacles.
Upon completion of this activity, participants should be able to:
- Assess the type, stage, and functional classification of heart failure in hospitalized patients
- Develop a patient-centered, guideline-directed, evidence-based management plan for patients hospitalized with heart failure with reduced ejection fraction (HFrEF)
- Integrate data on newer agents approved for HFrEF to ensure safe and appropriate administration in patients shortly after an acute episode
- Discuss the FDA recall of common heart failure medications and which agents have and have not been recalled
- Apply effective transitions of care strategies for the management of patients with HF
Barry Greenberg, MD
Department of Medicine
Director, Advanced Heart Failure Treatment Program
Department of Cardiology
University of California, San Diego
La Jolla, California
Physician Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™ Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Pharmacy Continuing Education
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for a total of 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Numbers – 0530-9999-19-110-H01-P
This is a knowledge-based activity.
Nursing Continuing Education Accreditation Statement
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Global Education Group.
Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Global Education Group are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
Barry Greenberg, MD
- Consultant: Actelion, Akcea, Amgen, Bayer, Cellular Dynamics, Ionis, Janssen, Mesoblast, MyoKardia, Novartis, Zensun
- Research: Sanofi
- Speakers’ Bureaus: Novartis, Zoll
The following planners and managers, Rachel Brown, PharmD, Ashley Marostica, RN, MSN, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period of September 12, 2019 through September 12, 2020 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Pharmacists must check the CPE monitor for credits within 60 days of the activity.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
For information about ANCC or ACPE accreditation of this activity, please contact Global Education Group at (303) 395-1782 or email@example.com.